TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients
Open Access
- 11 April 2020
- Vol. 12 (4), 946
- https://doi.org/10.3390/cancers12040946
Abstract
Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients with melanoma might be crucial for patient-tailored treatment choices. Mutations in the promoter region of the telomerase reverse transcriptase gene (TERTprom) lead to increased TERT expression and telomerase activity and are frequent in BRAFV600 mutant melanoma. Reportedly, TERTprom, and BRAFV600 mutations cooperate in driving cancer progression and aggressiveness. We evaluated the effect of the TERTprom status on the clinical outcome in 97 MAPKi-treated melanoma patients. We observed that patients with the c.-146C > T mutation showed a significantly worse progression-free survival (PFS) compared to those carrying the c.-124C > T mutation and a two-fold increased risk of progression (median 5.4 vs. 9.5 months; hazard ratio (HR) 1.9; 95% confidence interval (CI) 1.2–3.2; p = 0.013). This trend was also observed for the overall survival (OS); melanoma patients with the c.-146C > T mutation showed a poorer prognosis compared to those with the c.-124C > T mutation (median 13.3 vs. 25.5 months; HR 1.9, 95% CI 1.1–3.3, p = 0.023). Our results disclose a different correlation of the two TERTprom mutations with MAPKi-treated melanoma patient outcome, highlighting a different impact of the pathway blockade.Funding Information
- Istituto Oncologico Veneto (BIGID219MENI)
This publication has 29 references indexed in Scilit:
- Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine CareCancers, 2019
- TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the TrunkCancers, 2019
- TERT promoter mutation subtypes and survival in stage I and II melanoma patientsInternational Journal of Cancer, 2018
- Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancerNature Communications, 2018
- The new paradigm of systemic therapies for metastatic melanomaJournal of the American Academy of Dermatology, 2017
- TERT promoter mutations in melanoma survivalInternational Journal of Cancer, 2016
- Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activationNature, 2015
- The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancerScience, 2015
- TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous MelanomaJNCI Journal of the National Cancer Institute, 2014
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013